These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 15739617)

  • 41. [The direct antiviral effect of interferon-gamma on hepatitis C virus replicon].
    Jia YT; Wei L; Jiang D; Cong X; Fei R
    Zhonghua Gan Zang Bing Za Zhi; 2006 Jan; 14(1):7-10. PubMed ID: 16420756
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Studies on hepatitis C virus resistance to inhibitors in replicon systems.
    Zhao Y; Huang M
    Curr Protoc Pharmacol; 2010 Sep; Chapter 13():Unit 13B.2. PubMed ID: 22294367
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Exploration of the in vitro antiviral activity of a series of new pyrimidine analogues on the replication of HIV and HCV.
    Jafar NN; Al-Masoudi NA; Baqir SJ; Leyssen P; Pannecouque C
    Antivir Chem Chemother; 2012 Sep; 23(3):103-12. PubMed ID: 23010622
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A screen for novel hepatitis C virus RdRp inhibitor identifies a broad-spectrum antiviral compound.
    Madhvi A; Hingane S; Srivastav R; Joshi N; Subramani C; Muthumohan R; Khasa R; Varshney S; Kalia M; Vrati S; Surjit M; Ranjith-Kumar CT
    Sci Rep; 2017 Jul; 7(1):5816. PubMed ID: 28725041
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Replication of the hepatitis C virus in cell culture.
    Bartenschlager R; Kaul A; Sparacio S
    Antiviral Res; 2003 Oct; 60(2):91-102. PubMed ID: 14638404
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cinnamic acid derivatives inhibit hepatitis C virus replication via the induction of oxidative stress.
    Amano R; Yamashita A; Kasai H; Hori T; Miyasato S; Saito S; Yokoe H; Takahashi K; Tanaka T; Otoguro T; Maekawa S; Enomoto N; Tsubuki M; Moriishi K
    Antiviral Res; 2017 Sep; 145():123-130. PubMed ID: 28780423
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Experimental models for hepatitis C virus (HCV): new opportunities for combating hepatitis C.
    Trujillo-Murillo Kdel C; Garza-Rodríguez Mdel L; Martínez-Rodríguez HG; Barrera-Saldaña HA; Bosques-Padilla F; Ramos-Jiménez J; Rivas-Estilla AM
    Ann Hepatol; 2004; 3(2):54-62. PubMed ID: 15257247
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Identification of natural compounds extracted from crude drugs as novel inhibitors of hepatitis C virus.
    Zheng X; Guo R; Liu Q; Wakae K; Watanabe N; Fukano K; Que L; Li Y; Aly HH; Watashi K; Suzuki R; Murayama A; Kato T; Aizaki H; Wakita T; Huang X; Yan Y; Song SJ; Muramatsu M
    Biochem Biophys Res Commun; 2021 Aug; 567():1-8. PubMed ID: 34130179
    [TBL] [Abstract][Full Text] [Related]  

  • 49. New perspectives in HCV therapy: entry inhibitors.
    Donia M; Cacopardo B; Libra M; Scalia G; McCubrey JA; Nicoletti F
    Recent Pat Antiinfect Drug Discov; 2010 Nov; 5(3):181-94. PubMed ID: 20497122
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Applications of computer-aided approaches in the development of hepatitis C antiviral agents.
    Ganesan A; Barakat K
    Expert Opin Drug Discov; 2017 Apr; 12(4):407-425. PubMed ID: 28164720
    [TBL] [Abstract][Full Text] [Related]  

  • 51. 3-drug synergistic interactions of small molecular inhibitors of hepatitis C virus replication.
    Grünberger C; Wyles DL; Kaihara KA; Schooley RT
    J Infect Dis; 2008 Jan; 197(1):42-5. PubMed ID: 18171283
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Hepatitis C virus RNA synthesis in a cell-free system isolated from replicon-containing hepatoma cells.
    Hardy RW; Marcotrigiano J; Blight KJ; Majors JE; Rice CM
    J Virol; 2003 Feb; 77(3):2029-37. PubMed ID: 12525637
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Lifestyle-related diseases of the digestive system: a new in vitro model of hepatitis C virion production: application of basic research on hepatitis C virus to clinical medicine.
    Saito S; Heller T; Yoneda M; Takahashi H; Nakajima A; Liang JT
    J Pharmacol Sci; 2007 Oct; 105(2):138-44. PubMed ID: 17928740
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Hepatitis C virus cell culture models: an encomium on basic research paving the road to therapy development.
    Lohmann V
    Med Microbiol Immunol; 2019 Feb; 208(1):3-24. PubMed ID: 30298360
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Advances in genomic research on hepatitis C virus with a useful tool, replicon system.
    Nakamura M; Saito H; Hibi T
    Keio J Med; 2008 Jun; 57(2):75-83. PubMed ID: 18677087
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Lobohedleolide suppresses hepatitis C virus replication via JNK/c-Jun-C/EBP-mediated down-regulation of cyclooxygenase-2 expression.
    Lin CK; Tseng CK; Liaw CC; Huang CY; Wei CK; Sheu JH; Lee JC
    Sci Rep; 2018 Jun; 8(1):8676. PubMed ID: 29875371
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clearance of replicating hepatitis C virus replicon RNAs in cell culture by small interfering RNAs.
    Randall G; Grakoui A; Rice CM
    Proc Natl Acad Sci U S A; 2003 Jan; 100(1):235-40. PubMed ID: 12518066
    [TBL] [Abstract][Full Text] [Related]  

  • 58. New insights into HCV replication: potential antiviral targets.
    Rice CM
    Top Antivir Med; 2011; 19(3):117-20. PubMed ID: 21946389
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Shape-based virtual screening, synthesis and evaluation of novel pyrrolone derivatives as antiviral agents against HCV.
    Bassetto M; Leyssen P; Neyts J; Yerukhimovich MM; Frick DN; Brancale A
    Bioorg Med Chem Lett; 2017 Feb; 27(4):936-940. PubMed ID: 28089348
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Mechanisms of hepatitis C virus infection.
    Moriishi K; Matsuura Y
    Antivir Chem Chemother; 2003 Nov; 14(6):285-97. PubMed ID: 14968935
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.